Indicators of Kidney Fibrosis in Patients with Type 2 Diabetes and Chronic Kidney Disease Treated with Dulaglutide.
Saved in:
| Title: | Indicators of Kidney Fibrosis in Patients with Type 2 Diabetes and Chronic Kidney Disease Treated with Dulaglutide. |
|---|---|
| Authors: | Tuttle KR; Providence Healthcare, University of Washington, Spokane, Washington, USA., Wilson JM; Eli Lilly and Company, Indianapolis, Indiana, USA., Lin Y; Eli Lilly and Company, Indianapolis, Indiana, USA., Qian HR; Eli Lilly and Company, Indianapolis, Indiana, USA., Genovese F; Nordic Bioscience, Herlev, Denmark., Karsdal MA; Nordic Bioscience, Herlev, Denmark., Duffin KL; Eli Lilly and Company, Indianapolis, Indiana, USA., Botros FT; Eli Lilly and Company, Indianapolis, Indiana, USA. |
| Source: | American journal of nephrology [Am J Nephrol] 2023; Vol. 54 (1-2), pp. 74-82. Date of Electronic Publication: 2023 Feb 08. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Karger Country of Publication: Switzerland NLM ID: 8109361 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1421-9670 (Electronic) Linking ISSN: 02508095 NLM ISO Abbreviation: Am J Nephrol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
